¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time gain compensation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
  • synaptic time
    ½Ã³À½ºÅë°ú½Ã°£, ¿¬Á¢Åë°ú½Ã°£
  • sedimentation time
    ħ°­½Ã°£
  • sinoatrial conduction time
    ±¼½É¹æÀüµµ½Ã°£, µ¿½É¹æÀüµµ½Ã°£
  • sinus node recovery time
    ±¼°áÀýȸº¹½Ã°£, µ¿°áÀýȸº¹½Ã°£
  • tear film breakup time
    ´«¹°¸·ÆÄ±«½Ã°£
  • utilization time
    ÀÌ¿ë½Ã°£
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • zero-time shift
    ¿øÁ¡À̵¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • repetition time
    ¹Ýº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • time dose relationship
    ½Ã°£¿ë·®°ü°è
  • time-kill rate
    ½Ã°£»ç¸ê¼Óµµ
  • sedimentation time
    ħÀü½Ã°£
  • sinoatrial conduction time
    ±¼½É¹æÀüµµ½Ã°£
  • sinus node recovery time
    ±¼°áÀýȸº¹½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • delay time
    Áö¿¬ ½Ã°£
  • dextrinizing time
    ÀüºÐÀüÈ­½Ã°£(îþÝÏï®ûùãÁÊà).
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£.
  • diffusion time
    È®»ê½Ã°£
  • disappearance time =DT
    ¹æ»ç ¼Ò½Ç½Ã°£.
  • dodging time
    ºÒ±ÔÄ¢Àû Åë°æ±â°£¡ì¿ÏÀü¿ù°æÆóÁö±îÁöÀÇ ºÎÁ¤±â¡í.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • doubling time
    ¹è°¡½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • doubling time
    ¹è°¡½Ã°£(ÛÃÊ¥ãÁÊà).
  • echo time (TE)
    ¿¡ÄÚ ½Ã°£
  • ejection time
    ¹ÚÃâ½Ã°£(ÚÑõóãÁÊà).
  • elapsed time
    °æ°ú ½Ã°£
  • empyting time
    ¹èÃâ½Ã°£(ÛÉõóãÁÊà)
  • euglobin clot lysis time
    À¯±Û·ÎºÒ¸°ÀÀ±«¿ëÇØ½Ã°£, À¯±Û·ÎºóÀÀ±«À¶Çؽð£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MICRA Medical Injury Compensation Reform Act
NCS National Collaborative Study; neocarcinostatin; nerve conduction study; newborn calf serum; no conce...
RC an electronic circuit containing a resistor and capacitor in series; radiocarpal; reaction center; r...
RCE reasonable compensation equivalent
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
BHT Breath-holding time
t C)-time
CCT Central Conduction Time
CMCT Central Motor Conduction Time
CRT Choice Reaction Time
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 6
energy confinement time <radiobiology> Characteristic time in which 1/e (or sometimes 1/2) of a system's energy is lost to its surroundings.
In a plasma device, the energy loss time (or the energy confinement time) is one of three critical parameters determining whether enough fusion will occur to sustain a reaction.
See: Lawson criterion.
(09 Oct 1997)
energy replacement time <radiobiology> Time required for a plasma to lose (via radiation or other loss mechanisms) an amount of energy equal to its average kinetic energy.
(09 Oct 1997)
euglobulin clot lysis time A measure of the ability of plasminogen activators and plasmin to lyse a clot; normally, clot lysis is determined by the balance of factors which activate fibrinolysis (plasminogen activators and plasmin) and those which inhibit lysis; in certain conditions (e.g., carcinoma or hepatic insufficiency) activating factors predominate and can be measured by noting the time it takes the euglobulin fraction of plasma (excluding inhibitors of fibrinolysis) to clot.
(05 Mar 2000)
fading time The time required for a constant stimulus applied to a fixed area of the peripheral visual field to stop.
(05 Mar 2000)
zero time-binding DNA DNA that has become the duplex form at the start of a reassociation process.
Acronym: DNA
(05 Mar 2000)
utilization time The minimum duration of a stimulus of rheobasic strength that is just sufficient to produce excitation.
Synonym: temps utile.
(05 Mar 2000)
forced expiratory time The time taken to expire a given volume or a given fraction of vital capacity during measurement of forced vital capacity; subscripts specify the exact parameters measured.
(05 Mar 2000)
left ventricular ejection time The time measured clinically from onset to incisural notch of the carotid or other pulse; properly the time of ejection of blood from the left ventricle beginning with aortic valve opening and ending with aortic valve closure.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • half time
    ¹ÝÀÏ ³ëµ¿;¹ÝÀϱÞ;Áß°£ ÈÞ½Ä
  • high time
    ÁÁÀº ¶§(½Ã±â);È£±â;Èï°Ü¿ï(À¯ÄèÇÑ)¶§
  • hold time
    (·ÎÄÏ,¹Ì»çÀÏ ¹ß»ç½ÃÀÇ ÃÊÀбâ,ÀÛ¾÷ µîÀÇ)ÀϽÃÀû Áß´Ü(´ë±â)
  • lap time
    ÇÑ ¹ÙÄû µµ´Â ½Ã°£;ÀÏÁֽð£
  • lead time
    ±âȹ¿¡¼­ »ý»ê±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£
  • local time
    Áö¹æ½Ã;ÇöÁö ½Ã°£
  • machine time
    (ÄÄÇ»ÅÍ µîÀÇ) ÃÑ ÀÛµ¿½Ã(°£);ÀÛµ¿ ¿¬½Ã°£
  • mean solar time
    Æò±Õ žç½Ã;Æò±Õ½Ã
  • monkey time
    ¼­¸Ó ŸÀÓ
  • mountain time
    »êÁö Ç¥ÁؽÃ
  • needle time
    (¿µ)(¹æ¼Û)·¹ÄÚµå À½¾Ç½Ã°£
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • part time
    Á¤»ó(±Ù¹«)½Ã°£ÀÇ ÀϺÎ
  • post time
    ¿ìÆí ¹ß¼Û ½Ã°£;¿ìÆí Áý¹è ½Ã°£;·¹À̽º ÃâÀü ¿¹Á¤ ½Ã°£
  • prime time
    (¶óµð¿À,ÅÚ·¹ºñÀüÀÇ)°ñµç ¾Æ¿ö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á